CMO
HZNP

Covenant Multifamily Offices’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Covenant Multifamily Offices’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$233K Buy
+2,049
New +$213K 0.04% 213

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Covenant Multifamily Offices's HZNP Position: Q3 2021 in Review

Covenant Multifamily Offices opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2021: 2,049 shares worth $233K. The stake represents 0.04% of the portfolio and ranks #213 among its holdings.

572 funds tracked by Wall St. Rank hold HZNP as of Q3 2021.

  • Covenant Multifamily Offices held 2,049 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $233K as of Q3 2021.
  • Horizon Therapeutics Public Limited Company Ordinary Shares was a new Covenant Multifamily Offices position in Q3 2021.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.04% of Covenant Multifamily Offices's portfolio in Q3 2021, its #213 holding.
  • 572 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2021.

Based on Covenant Multifamily Offices's 13F filing for Q3 2021, filed 21 Oct 2021.